Technical supplement - COVID-19 Australia: Epidemiology reporting

Last updated 10 December 2021

COVID-19 National Incident Room Surveillance Team

# Summary

This supplement to the series of regular Australian coronavirus disease 2019 (COVID-19) epidemiological reports describes the technical background to the surveillance data reported through Communicable Diseases Network Australia (CDNA) as part of the nationally-coordinated response to COVID-19.

# Background

Coronavirus disease 19 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in humans in Wuhan, China, in December 2019. The disease subsequently spread rapidly, leading to a global pandemic.1 The predominant modes of transmission for COVID-19 are through direct or close contact with an infected person via respiratory droplets, or indirectly via contact with contaminated fomites.2 The median incubation period of COVID-19 is 5–6 days, ranging from 1 to 14 days.3,4 The infectious period remains uncertain; however, it is estimated to be from 48 hours before symptoms develop until two weeks after symptom onset.3,5 The predominant symptoms reported in COVID-19 cases are cough, sore throat, fatigue, runny nose and fever.6 The majority of cases recover from the disease without clinical intervention; however, approximately 20% of global cases result in more severe outcomes, such as shortness of breath and pneumonia, necessitating hospitalisation and the requirement of additional oxygen or ventilation.7,8 Severe or fatal outcomes are generally more common among elderly cases or those with comorbid conditions.8 A visual depiction of the severity spectrum of COVID-19, and of the data sources that we use in this report to measure aspects of severity, is provided in Figure 1.

****Figure 1: Severity spectrum of COVID-19 cases and data sources used to measure severity in Australia****



# Data sources

## Notifications to health departments

The majority of data presented in the latest fortnightly report were derived from the National Interoperable Notifiable Diseases Surveillance System (NINDSS).[[1]](#footnote-2) COVID-19 is a notifiable disease under public health legislation in all states and territories and is listed on the National Notifiable Diseases List under the National Health Security Act (2007).9 Accordingly, all jurisdictions report confirmed and probable cases of COVID-19 through the NINDSS. The national case definition for surveillance is available in the COVID-19 Series of National Guidelines.10 Due to the dynamic nature of the NINDSS, numbers presented in the latest fortnightly report may be subject to revision and may vary from numbers previously reported and from case notifications released by states and territories. Case numbers for the most recent dates of illness onset may be subject to revision, due to reporting delays. Data for the latest fortnightly report, unless otherwise indicated, have been extracted from the NINDSS within 48 hours after the end of the reporting period, for notifications received up to the end of the reporting period. Data for COVID-19 deaths notified in the latest reporting period were extracted from daily notifications from state and territory health departments to the National Incident Room (NIR), received up to the end of the reporting period.

## Acute respiratory illness

We report data from surveillance systems that monitor trends in the number of people reporting symptoms of mild respiratory illnesses in the community and in primary care settings. These systems gathered information from across Australia and include the online FluTracking syndromic surveillance system,11 the Commonwealth General Practice (GP) Respiratory Clinics, and the Australian Sentinel Practice Research Network (ASPREN) and Victorian Sentinel Practice Influenza Network (VicSPIN) GP sentinel surveillance systems. These systems capture data on any respiratory illness experienced by participants, including pathogens such as SARS-CoV-2.

## Hospitalisations

To report on COVID-19 disease severity, we draw on hospitalisations and intensive care unit (ICU) admissions data provided from two sentinel surveillance systems: the Influenza Complications Alert Network (FluCAN)12 and the Short Period Incidence Study of Severe Acute Respiratory Infection Study (SPRINT-SARI),13 as well as NINDSS. FluCAN is a real-time hospital sentinel surveillance system for acute respiratory disease requiring hospitalisation. Established to monitor for seasonal influenza, FluCAN has been modified to include surveillance for COVID-19. Participating sites collect detailed clinical and laboratory information from all hospitalised patients with a confirmed diagnosis of COVID-19. SPRINT-SARI is a sentinel system that collects detailed data on the characteristics and outcomes of and interventions for patients admitted to ICUs or High Dependency Units (HDUs) with COVID-19 at participating sites across Australia. Data presented from both sentinel surveillance systems may be subject to retrospective adjustments following publication. Data on hospitalisations and ICU admissions from the NINDSS is also presented in the report. This is based on data from jurisdictions which have reliable data across both hospital and ICU data fields, and which do not routinely hospitalise cases for isolation purposes.

## Viral genomics

From Report 36 onwards, information on viral genomics is included in every second report. This information is provided by the National Analysis Team of the national pathogen genomic sequence and analysis platform, AusTrakka,[[2]](#footnote-3) and from jurisdictional pathogen sequencing laboratories. Reporting periods are based on sample collection date, not date of sequencing.

Not all samples will be suitable for sequencing, especially those samples with low amounts of viral nucleic acid (i.e., high RT-qPCR cycle thresholds) such as those collected from cases late in their disease episode (common in returned travellers) or those subjected to storage at suboptimal conditions (causing RNA degradation). Quality control for consensus sequences included: requiring ≥ 90% of the viral genome to be recovered; < 50 single nucleotide polymorphisms (SNPs) from the MN9008947.3 reference genome; and < 50 ambiguous or missing bases. Sequences with 50–90% genome recovery are assessed for potential inclusion.

Report 35 and earlier used data from the Global Initiative on Sharing All Influenza Data (GISAID), an international virus sequence database that provides open access to SARS-CoV-2 genomic data.14

SARS-CoV-2 genomic lineages are defined using the Phylogenetic Assignment of Named Global Outbreak (PANGO) lineage nomenclature.15 Lineages reflect evolutionary relationships and are hierarchically organised following the phylogenetic tree structure. The PANGO designation describes major lineages with letters of the alphabet (A, B, etc.), with sub- and sub-sub-lineages numbered and separated by dots (“.”). Thus, sub-lineage B.1.1 is contained with sub-lineage B.1, which is itself part of lineage B. The numbers at the same level are not indicative of a phylogenetic relationship. As such, B.1.1 is not necessarily more closely related to B.1.2 than to B.1.5. However, all the sub-lineages under B.1 are closer to each other than they are to B.2, for example. Only three sub-levels are permitted under this nomenclature system and sub-lineages under this will be assigned the next available alpha symbol (e.g. B.1.1.25.1 was reassigned to D.2 and B.1.1.28.1 was reassigned to P.1).

Lineage classifications can change retrospectively as new sequences are added and lineages diversify over time.[[3]](#footnote-4) Sequences that have been assigned higher-level lineage designations (e.g. B or B.1), where there are sub-lineages defined within the dataset (e.g. B.1.1, B.1.23 or B.1.1.25), may indicate a poor quality sequence; for example, a lower proportion of the genome recovered. Poor sequence quality can lead to uncertainty about the placement of the sequence into sub-lineages.

A “variant” refers to a set of viruses with the same or similar patterns of mutations, some of which are associated with increased transmissibility or virulence, or decreased effectiveness of public health measures. These are labelled as “variants of concern” (VOCs) and given specific identifiers (e.g. VOC-202012/01). However, as VOCs are usually defined not just by the unique set of mutations, but by membership of distinct lineage groups, they are often referred to by the lineage name. So VOC-202012/01 is often just referred to as B.1.1.7. It should be noted, though, that the lineage naming convention refers to evolutionary aspects of the virus, while the VOC-ID also takes into account the epidemiological behaviour of the virus.

On 31 May 2021 the WHO announced new nomenclature for key variants using letters of the Greek alphabet.16 This system was developed to assist with public discussion of variants, and aimed to provide labels that were easier to pronounce and non-stigmatising. The VOCs monitored in this reporting series will henceforth note both the genetic Pangolin lineage and the WHO label (if named).

The current VOCs reported in Australia are: B.1.1.7 (Alpha) (VOC-202012/01), B.1.351 (Beta) (VOC-20201202/02), P.1 (Gamma) (VOC-202101/02), B.1.617.2 (Delta) (VOC-21APR-02), and the B.1.1.529 (Omicron) lineage.

On 27 September 2021, Kappa (B.1.617.1), which had been classified as a VOC in Australia, was reclassified as a “variant of interest” (VOI) by the Communicable Diseases Genomics Network (CDGN) VOC Taskforce. As such, from report 52 onwards, Kappa is no longer included in this reporting series.

### B.1.1.7 (VOC-202012/01, Alpha)

The B.1.1.7 lineage is characterised by 17 mutations, including spike protein mutations N501Y and P681H, and a two-amino-acid deletion of residues 69,70 (IHV68I).17 Having first emerged in the United Kingdom in September 2020, it has now been detected in more than 90 countries worldwide.

### B.1.351 (501Y.V2, Beta)

The B.1.351 lineage is characterised by nine characteristic mutations, including spike protein mutations K417N, E484K and N501Y.18 In addition to potentially increased transmissibility, there is concern that the E484K mutation may affect antibody-mediated neutralisation of the virus.19 This variant was first detected in South Africa in October 2020 and has since been documented in more than 40 countries.

### P.1 (501Y.V3, Gamma)

The P.1 lineage is a sub-cluster within lineage B.1.1.28 that is characterised by 17 mutations, including the same spike protein mutations K417T, E484K and N501Y as B.1.351.20 The B.1.1.28 lineage was common to Brazil, but in December 2020 reports emerged from Brazil’s Amazonas region of a surge in cases associated with the P.1 lineage.21 In late December, the P.1 variant was reported in four COVID-19 cases in Japan detected during airport screening, and has now been seen in more than 20 countries.

### B.1.617.2 (VOC-21APR-02, Delta)

Lineage B.1.617 emerged from India in October 2020.22 Ongoing genomic surveillance has broken B.1.617 into three sub-lineages—B.1.617.1, B.1.617.2 and B.1.617.3—which vary in mutations in the spike protein.23 B.1.617.2 has been a particularly successful sub-lineage, with evidence of B.1.617.2 being associated with higher transmissibility and increased risk of hospitalisation.24

Public Health England and the World Health Organization (WHO) declared the B.1.617 lineage (PHE designed B.1.617.2 only) as a Variant of Concern on 7 May 2021 and 10 May 2021 respectively.24,25 With the declaration of new VOC nomenclature by the WHO on 1 June 2021,26 only the B.1.617.2 lineage was retained as a VOC by the WHO. In Australia, B.1.617.1 (VUI-21APR-01, Kappa) was classified as a VOC until 27 September 2021, when it was demoted to a VOI by the CDGN VOC taskforce.

There are now more than a hundred B.1.617.2 sub-lineages defined: AY.1 to AY.127. There are also a number of sub-lineages within the sub-lineages, as well as a few sub-lineages within those in turn. There has been no reported biological difference of the sub-lineages, and these are more reflective of geographical epidemiology. There appears to be some instability in the lineage assignment, with the sub-lineages being sensitive to the proportion of the genome recovered. Therefore, the CDGN VOC Taskforce has decided to report all sub-lineage samples as just B.1.617.2, Delta.

The B.1.617.1 and B.1.617.3 lineages continue to be monitored by AusTrakka, but are not reported.

### B.1.1.529 (Omicron)

Lineage B.1.1.529 emerged in South Africa in November 2021,27 and was designated a VOC by the WHO on 26 November 2021.28 This VOC contains numerous mutations, including 32 mutations in the spike protein, many of which have been seen in other VOCs. The limited evidence currently available suggests that Omicron is rapidly increasing in South Africa compared to Delta and is possibly becoming the dominant lineage. A high number of reinfections have recently been reported in South Africa, despite a large recent wave of Delta infections (although vaccine coverage is low, which may limit generalisation to other highly vaccinated populations). There is currently insufficient data available to assess whether Omicron causes more severe clinical disease than other variants; however, some of the mutations are predicted to affect its susceptibility to neutralising antibodies (from vaccination or prior infection), innate immunity, and monoclonal antibody therapies.

As yet, there is limited evidence available on what impact the combination of mutations will have on transmission, vaccine efficacy or disease severity; however, this will be very closely monitored by the CDGN VOC Working Group. Surveillance for B.1.1.529 sequences in Australia, through genomics, will be undertaken via the CDGN and AusTrakka.

The term ‘Omicron-like’ is reported where a sequence has at least 20, but a maximum of 30, of the 45 defined Omicron mutations. These sequences are reported according to the CDGN VOC laboratory confirmed definition.29

## Testing data

Testing data by demographic breakdown were reported on a weekly basis by jurisdictions.

## Denominators

Population data from the Australian Bureau of Statistics (ABS) Estimated Resident Population are used to estimate rates of infection by jurisdiction, age group, sex and Indigenous status. From Report 37 onwards, Estimated Resident Population data as at June 2020 is used. Previous reports used Estimated Resident Population data as at December 2019.

## International

All data reported in the international section were extracted from the World Health Organization (WHO) Dashboard on the last day of the reporting period unless otherwise specified.30

# Definitions

**“Cluster”** in relation to COVID-19 refers to two or more cases (who do not reside in the same household) that are epidemiologically related in time, place or person where a common source (such as an event or within a community) of infection is suspected but not yet established.

**“COVID-19”** is the disease caused by a novel coronavirus—SARS-CoV-2—that emerged in China in late 2019. ‘CO’ stands for corona-, ‘V’ stands for virus, ‘ID’ stands for infectious disease, and ‘-19’ refers to the year that this disease was first reported.

“**COVID-19 associated death**” is defined for surveillance purposes as a death in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 (e.g. trauma).31 There should be no period of complete recovery from COVID-19 between illness and death. Where a Coroner’s report is available, these findings are to be observed.

**“Diagnosis date”** is derived from data collected by the NINDSS and represents the reported true onset of disease date. If unknown, the earliest of specimen collection date, notification date or notification received date is used.

**“Initial investigation”** refers to the process of determining whether an infection was acquired locally (within Australia) or overseas. Cases under initial investigation have yet to be classified as locally or overseas acquired.

“**Notification received date”** is reported in the NINDSS and represents the date the notification of the disease was first received by the communicable disease section of the health authority. As notification can only occur after testing is completed and information processed, counts for a defined period will vary according to the date type used.

**“Ongoing investigation”** refers to the process of determining the definitive source of infection for locally-acquired cases. Cases under ongoing investigation are known to be locally acquired but require further follow-up to determine the precise source of infection.

“**Outbreak”** in relation to COVID-19 refers to two or more cases (who do not reside in the same household) among a specific group of people and/or over a specific period of time where illness is associated with a common source (such as an event or within a community). Some states and territories may report a single case associated with a residential aged care facility as an outbreak.

**“SARS-CoV-2”** is the virus that causes the disease COVID-19. It is a betacoronavirus genetically related to the 2003 Severe acute respiratory syndrome coronavirus (SARS-CoV).

**“True onset date”** (previously “date of illness onset”) is reported in the NINDSS and represents the earliest date the case exhibited symptoms.

# Acknowledgements

This supplement describes the technical background to the surveillance data reported through Communicable Diseases Network Australia (CDNA) as part of the nationally-coordinated response to COVID-19. We thank public health staff from incident emergency operations centres and public health units in state and territory health departments, and the Australian Government Department of Health, along with state and territory public health laboratories. We thank those who have provided data from surveillance systems, such as Commonwealth respiratory clinics, ASPREN, Flutracking, SPRINT-SARI, FluCAN, Communicable Disease Genomics Network, AusTrakka and jurisdictional sequencing laboratories.

# Author details

## Corresponding author

COVID-19 National Incident Room Surveillance Team Australian Government Department of Health, GPO Box 9484, MDP 14, Canberra, ACT 2601.
Email: epi.coronavirus@health.gov.au

# References

1. World Health Organization (WHO). Speeches detail: WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. [Internet.] Geneva: WHO; 11 March 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
2. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific brief. [Internet.] Geneva: WHO; 9 July 2020. [Accessed on 14 October 2020.] Available from: https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions.
3. McAloon C, Collins Á, Hunt K, Barber A, Byrne AW, Butler F et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open. 2020;10(8). doi: https://doi.org/10.1136/bmjopen-2020-039652.
4. Australian Government Department of Health. Australian National Disease Surveillance Plan for COVID-19. [Internet.] Canberra: Australian Government Department of Health; 30 May 2020. Available from: https://www.health.gov.au/resources/publications/australian-national-disease-surveillance-plan-for-covid-19.
5. Yuan Z, Xiao Y, Dai Z, Huang J, Zhang Z, Chen Y. Modelling the effects of Wuhan’s lockdown during COVID-19, China. Bull World Health Organ. 2020;98(7):484–94.
6. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109. doi: https://doi.org/10.1016/j.jaut.2020.102433.
7. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020; 127. doi: https://doi.org/10.1016/j.jcv.2020.104371.
8. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: WHO; 2020. [Accessed on 14 October 2020.] Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
9. Australian Government Federal Register of Legislation. National Health Security Act 2007. No. 174, 2007. Compilation No. 15. [Legislation.] Canberra: Australian Government, Federal Register of Legislation; 19 July 2016. Available from: https://www.legislation.gov.au/Details/C2016C00847.
10. Australian Government Department of Health. Coronavirus Disease 2019 (COVID-19): CDNA national guidelines for public health units. Canberra: Australian Government Department of Health; 11 January 2021. [Accessed on 18 January 2021.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/7A8654A8CB144F5FCA2584F8001F91E2/$File/COVID-19-SoNG-v4.1.pdf.
11. Dalton C, Durrheim D, Fejsa J, Francis L, Carlson S, d’Espaignet ET et al. Flutracking: a weekly Australian community online survey of influenza-like illness in 2006, 2007 and 2008. Commun Dis Intell Q Rep. 2009;33(3):316–22.
12. Monash Health. FluCAN (Influenza surveillance): FluCAN (The Influenza Complications Alert Network) [Internet.] Melbourne: Monash Health; 2020. Available from: https://monashhealth.org/services/monash-infectious-diseases/research/influenza-research/flucan-influenza-surveillance-2/.
13. Australian and New Zealand Intensive Care Society (ANZICS). SPRINT-SARI: Short period incidence study of severe acute respiratory infection. [Internet.] Camberwell: ANZICS; 2020. Available from: https://www.anzics.com.au/current-active-endorsed-research/sprint-sari/.
14. Global Initiative on Sharing All Influenza Data (GISAID). [Website.] Berlin: Federal Republic of Germany, Freunde von GISAID e.V.; 2020. Available from: https://www.gisaid.org/.
15. Rambaut A, Homles EC, O’Toole Á, Hill V, McCrone JT, Ruis C et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5:1403–7. doi: https://doi.org/10.1038/s41564-020-0770-5.
16. WHO. Tracking SARS-CoV-2 variants. [Internet.] Geneva: WHO; 1 June 2021. [Accessed on 10 June 2021.] Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
17. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. [Internet.] Virological. December 2020. Available from: https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.
18. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438-43. doi: https://doi.org/10.1038/s41586-021-03402-9.
19. Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. bioRxiv. 2021. doi: https://doi.org/10.1101/2021.01.13.426558.
20. Faria NR, Claro IM, Candido D, Moyses Franco L, Andrade PS, Coletti TM et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. [Internet.] Virological. 13 January 2021. Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586.
21. Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. [Internet.] Virological. 12 January 2021. Available from: https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585.
22. Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN). Proposed new B.1 sublineage circulating in India #38. [Webpage.] San Francisco: GitHub; 30 March 2021. [Accessed on 18 October 2021.] Available from: https://github.com/cov-lineages/pango-designation/issues/38.
23. Public Health England (PHE). SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 9. London: United Kingdom Government Department of Health and Social Care, PHE; 22 April 2021. [Accessed on 18 October 2021.] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/979818/Variants\_of\_Concern\_VOC\_Technical\_Briefing\_9\_England.pdf.
24. PHE. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 10. London: United Kingdom Government Department of Health and Social Care, PHE; 7 May 2021. [Accessed on 18 October 2021.] Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/984274/Variants\_of\_Concern\_VOC\_Technical\_Briefing\_10\_England.pdf.
25. WHO. Weekly epidemiological update on COVID-19 - 11 May 2021. [Internet.] Geneva: WHO; 11 May 2021. [Accessed on 18 October 2021.] Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2021.
26. WHO. Weekly epidemiological update on COVID-19 - 1 June 2021. [Internet.] Geneva: WHO; 1 June 2021. [Accessed on 18 October 2021.] Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2021.
27. Network for Genomic Surveillance in South Africa (NGS-SA). Recording: Briefing on COVID-19 and vaccination programme developments 25 November 2021. [Video recording.] Durban: NGS-SA; 25 November 2021. [Accessed on 10 December 2021.] Available from: https://sacoronavirus.co.za/2021/11/25/recording-briefing-on-covid-19-and-vaccination-programme-developments-25-november-2021/.
28. WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. [Internet.] Geneva: WHO; 26 November 2021. [Accessed on 10 Decmber 2021.] Available from: https://www.who.int/news-room/statements/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
29. Communicable Diseases Genomics Network (CDGN). Variants of concern. Melbourne: CDGN; 2021. [Accessed on 10 December 2021.] Available from: https://www.cdgn.org.au/variants-of-concern.
30. WHO. WHO Coronavirus Disease (COVID-19) dashboard. [Internet.] Geneva: WHO; 2021. Available from: https://covid19.who.int/.
31. Australian Bureau of Statistics. Articles. Measuring excess mortality in Australia during the COVID-19 pandemic: methodology. [Internet.] Canberra: Australian Bureau of Statistics; 25 November 2020. [Accessed on 25 November 2020.] Available from: https://www.abs.gov.au/articles/measuring-excess-mortality-australia-during-covid-19-pandemic#methodology.

# ****Appendix A: Definitions for outbreak settings****

|  |  |
| --- | --- |
| Setting | Inclusions |
| Accommodation & housing | Includes high-density housing; hostels and backpackers; hotels and serviced apartments; public housing; rough sleeping; and temporary accommodation. |
| Aged care | Includes residential aged care facilities; commonwealth aged care facilities; and home-care. |
| Healthcare (excl. hospital) | Includes primary care; and allied health services. |
| Hospital | Includes inpatient acute and sub-acute hospital (including psychiatric units); day surgeries; and transitional care. |
| Childcare | Includes preschool child care services; and childcare services provided from home. |
| Educational facility (excl. childcare) | Includes schools; universities; TAFE; kindergarten; after-school care; other education and training facilities; and higher educational facilities. |
| Workplace/industry | Includes warehouses (not food); supermarkets; utilities; residential work sites; office spaces; manufacturing; logistics; food distribution centres; construction sites; retail and supermarkets. |
| Disability services | Includes disability services and private accommodation; and support services. |
| Food industry | Includes abattoirs; factory-based food production; meat and poultry processing facilities; food production (commercial fishing, grain, dairy); and fruit or vegetable farming. |
| Hospitality & entertainment | Includes cinemas and theatres; bars and music venues; and food premises (e.g. restaurants; takeaway food; cafes). |
| Travel & transport | Includes travel groups; cruise ships; cargo ships; mass transport (flights, trains, trams, buses); and other transport services (Uber and taxi). |
| Justice & emergency | Includes emergency services; correctional facilities; and prisons. |
| Other | Includes other various settings not captured by the other exposure settings, e.g. extended family gatherings (where two or more separate households come together); religious services; and sports and recreation venues. |

# Appendix B: Frequently asked questions

**Q: Where can I find more detailed data on COVID-19 cases?**
A: We are currently looking into ways to provide more in-depth epidemiological analyses of COVID-19 cases, with regard to transmission and severity, including hospitalisation. These analyses will continue to be built upon in future iterations of the CDI report.

**Q: Can I request access to the COVID-19 data behind your CDI fortnightly reports?**
A: National notification data on COVID-19 confirmed cases is collated in the National Interoperable Notifiable Diseases Surveillance System (NINDSS) based on notifications made to state and territory health authorities under the provisions of their relevant public health legislation.

Normally, requests for the release of data from the NINDSS requires agreement from states and territories via the Communicable Diseases Network Australia (CDNA), and, depending on the sensitivity of the data sought and proposed, ethics approval may also be required.

For information on how to apply to access data from the NINDSS please contact the NINDSS Data Requests inbox.[[4]](#footnote-5) We can then provide you with further information about the process and the required data request forms. Please note data requests for NINDSS data, including COVID data, will continue to be processed in line with CDNA policies and procedures. The time it takes to process your request may vary depending on the type(s) of data you request and the necessary approval steps.

We will continue to publish regular summaries and analyses of the NINDSS dataset and recommend the following resources be referred to in the meantime:

* NINDSS summary tables;[[5]](#footnote-6)
* Daily case summary of cases;[[6]](#footnote-7)
* Communicable Diseases Intelligence COVID-19 epidemiology report;
* State and territory public health websites. [[7]](#footnote-8)

**Q: Can I request access to data at postcode level of confirmed cases?**
A: Data at this level cannot be released without ethics approval and permission would need to be sought from all states and territories via CDNA. As noted above, specific requests for NINDSS data are currently on hold.

Where current or recent reported case numbers are high enough to justify it, a GIS/mapping analysis of cases will be included in the CDI COVID-19 epidemiology report. In order to protect privacy of confirmed cases, data in this map will be presented at SA3 level.

**Q: Where do I find the COVID-19 background information which was included as Appendix A in previous fortnightly epidemiology reports?**
A: This information was most recently published in Epidemiology Report 24[[8]](#footnote-9). Additional information can be found in the CDNA Series of National Guidelines (SoNG) for COVID-19.[[9]](#footnote-10)

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection and Response, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Jennie Hood

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection and Response, Australian Government Department of Health, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2021 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>

1. Previously known as the National Notifiable Diseases Surveillance System (NNDSS). [↑](#footnote-ref-2)
2. www.cdgn.org.au/austrakka. [↑](#footnote-ref-3)
3. Additional detailed information on SARS-CoV-2 lineages can be found at https://cov-lineages.org/descriptions.html. [↑](#footnote-ref-4)
4. nndss.datarequests@health.gov.au. [↑](#footnote-ref-5)
5. http://www9.health.gov.au/cda/source/cda-index.cfm. [↑](#footnote-ref-6)
6. https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers. [↑](#footnote-ref-7)
7. https://www1.health.gov.au/internet/main/publishing.nsf/Content/novel\_coronavirus\_2019\_ncov\_weekly\_epidemiology\_reports\_australia\_2020.htm [↑](#footnote-ref-8)
8. https://doi.org/10.33321/cdi.2020.44.75. [↑](#footnote-ref-9)
9. https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-novel-coronavirus.htm [↑](#footnote-ref-10)